Retraction Retraction dated 2021-10-12
Click to view Retraction: https://doi.org/10.1186/s13550-020-00734-x
-
Authors
Hughes, Daniel Johnathan https://orcid.org/0000-0003-2641-7632
Chand, Gitasha https://orcid.org/0000-0003-3565-3901
Goh, Vicky https://orcid.org/0000-0002-2321-8091
Cook, Gary J. R. https://orcid.org/0000-0002-8732-8134
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02978196 at ClinicalTrials.govDocuments that mention this clinical trial
RETRACTED ARTICLE: Inter- and intraobserver agreement of the quantitative assessment of [99mTc]-labelled anti-programmed death-ligand 1 (PD-L1) SPECT/CT in non-small cell lung cancer
https://doi.org/10.1186/s13550-020-00734-x
- License Information
-
More Information
Article History
Received: 8 September 2020
Accepted: 23 November 2020
First Online: 1 December 2020
Change Date: 12 October 2021
Change Type: Correction
Change Details: This article has been retracted. Please see the Retraction Notice for more detail:
Change Details: https://doi.org/10.1186/s13550-021-00851-1
Ethics approval and consent to participate
: Institutional ethics approval for this study was obtained from Shanghai General Hospital Ethics Committee (2016KY220). Participants enrolled in the study provided written informed consent to participate.
: Not applicable.
: DJH has received honoraria from Novartis and research funding from NanoMab Technology Limited. GC provides consultancy for NanoMab Technology Limited. VG has received research support from Siemens Healthcare. GJRC has received research support from NanoMab Technology Ltd., Theragnostics Ltd. and Serac Healthcare Ltd. and provides consultancy for GE Healthcare and NanoMab Technology Ltd.
